Drug Trial Radar · NCT05137054
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
317
Planned (sponsor's estimate)
Start
Aug 17, 2022
Primary completion
Mar 25, 2028
Study completion Mar 24, 2032
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Nov 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again. In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evidence of myeloma in their bodies). This study is the first time linvoseltamab will be combined with other cancer therapies. The main goal is to understand if linvoseltamab can be given safely with other cancer treatments, and if so, what dose of linvoseltamab should be used for each combination. The study is looking at several other research questions, including: * How many participants treated with linvoseltamab in combination with each of the other cancer treatments have improvement of their multiple myeloma * What side effects may happen from taking linvoseltamab together with another cancer treatment * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)
Conditions
- Multiple Myeloma
Interventions
LinvoseltamabDrug
Administered per the protocol
DaratumumabDrug
Administered per the protocol
CarfilzomibDrug
Administered per the protocol
LenalidomideDrug
Administered per the protocol
BortezomibDrug
Administered per the protocol
PomalidomideDrug
Administered per the protocol
IsatuximabDrug
Administered per the protocol
FianlimabDrug
Administered per the protocol
CemiplimabDrug
Administered per the protocol
NirogacestatDrug
Administered per the protocol
CevostamabDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLTs) for each study regimen during the observation periodTime frame: Up to 28 Days
- Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 5 Years
- Severity of TEAEsTime frame: Up to 5 Years
- Incidence of Serious Adverse Events (SAEs)Time frame: Up to 5 Years
- Severity of SAEsTime frame: Up to 5 Years
- Incidence of Adverse Events of Special Interest (AESIs)Time frame: Up to 5 Years
- Severity of AESIsTime frame: Up to 5 Years
- Incidence of laboratory abnormalitiesTime frame: Up to 5 Years
Locations
42 sites in 5 countries. Site status is shown where the registry gives one.
Scripps Clinic Torrey Pines
La Jolla, California · Recruiting
Winship Cancer Institute of Emory University
Atlanta, Georgia · Recruiting
Indiana University Health Simon Cancer Center
Indianapolis, Indiana · Recruiting
Dana Farber/Harvard Cancer Center
Boston, Massachusetts · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Weill Cornell Medicine/New York Presbyterian Hospital
New York, New York · Recruiting
New York Presbyterian Hospital Columbia University Medical Center
New York, New York · Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
Wake Forest University Health Sciences
Winston-Salem, North Carolina · Recruiting
The Ohio State University James Cancer Hospital
Columbus, Ohio · Recruiting
University of Texas Southwestern
Dallas, Texas · Recruiting
VA Puget Sound Health Care System
Seattle, Washington · Recruiting
Centre Hospitalier Universitaire Angers
Angers, France · Recruiting
CHU Montpellier - Departement D'Hematologie
Montpellier, France · Recruiting
Saint Antoine Hospital
Paris, France · Recruiting
Institut Gustave Roussy
Villejuif, France · Recruiting
Hospital Henri Mondor
Créteil, Île-de-France Region, France · Recruiting
Saint Louis Hospital
Paris, Île-de-France Region, France · Recruiting
Hopital Necker
Paris, Île-de-France Region, France · Recruiting
Centre Hospitalier Universitaire (CHU) de Poitiers
Poitiers, New Aquitaine, France · Recruiting
CHU de Lille - Rue Michel Polonovski
Lille, Nord, France · Recruiting
Nantes University Hospital
Nantes, Pays de la Loire Region, France · Recruiting
General Hospital of Athens Alexandra
Athens, Greece · Recruiting
Evangelismos General Hospital
Athens, Attica, Greece · Recruiting
Rambam Health Care Campus
Haifa, Israel · Recruiting
Hadassah Medical Center
Jerusalem, Israel · Recruiting
Sheba Medical Center
Ramat Gan, Central District, Israel · Recruiting
Hospital Universitario Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital Clinic de Barcelona
Barcelona, Spain · Recruiting
Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals,
Barcelona, Spain · Recruiting
Universitaru Hospital La Princesa
Madrid, Spain · Recruiting
Clinica Universidad de Navarra - Madrid
Madrid, Spain · Recruiting
Hospital Universitario Ramon y Cajal - Servicio de Psiquiatria
Madrid, Spain · Recruiting
University Hospital and Research Institute
Madrid, Spain · Recruiting
Hospital Universitario HM Sanchinarro
Madrid, Spain · Recruiting
University Hospital of Salamanca
Salamanca, Spain · Recruiting
Hospital Clinico Universitario de Santiago
Santiago de Compostela, A Coruna, Spain · Recruiting
Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain · Recruiting
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, Spain · Recruiting
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.